Podcast
AI in Healthcare and Life Sciences Podcast
Hosted by Emerj Technology Research · EN
The AI in Healthcare and Life Sciences is for non-technical leaders interested in where AI is creating an impact for patients, for business workflows, and for the bottom line.
Global Fortune 500 healthcare and life sciences leaders join Emerj AI Research team (and CEO Daniel Faggella) to share where they're seeing AI impact today, as well as best-practices for AI adoption and ROI measurement in healthcare and pharma.
Visit our advertising page to learn more about reaching our executive audience of AI adopters in the world's largest banking and insurance firms: https://emerj.com/advertise
11episodes
Episodes
Newest firstAll episodes
Rethink Healthcare Workforce Strain with Data Enablement - with Tony Pastorino of Resultant
3w ago00:31:06Tap to summarizeClinician burnout takes hold long before most healthcare leaders see it, and the signals that could forecast it are often already being collected, but locked inside systems and teams that don't communicate. In this episode, Tony Pastorino, Director of Healthcare Strategy at Resultant, examines how a shift from data governance to what he calls "data enablement", paired with predictive analytics and direct conversations with frontline staff, allows leaders to address workforce strain before it reaches clinicians. The conversation covers the operational blind spots that obscure early workload signals, the KPIs that distinguish genuine strain reduction from metric redistribution, the structural decisions that must precede any AI tooling, and the collaborative governance model that enables responsible AI in healthcare. Learn how brands work with Emerj and other Emerj Media options at http://go.emerj.com/partner2
Transcribe →
Driving the Transformation of Drug Discovery Through AI‑Ready Data Foundations - with Barry Bunin of CDD
Apr 1300:28:37Tap to summarizePersistent friction between experimental, computational, chemistry, and biology teams continues to slow discovery work, largely due to siloed data and tools that are too difficult for scientists to adopt. In this episode, Barry Bunin, CEO & President at Collaborative Drug Discovery, examines how simplifying data capture and creating a shared source of truth enables faster iteration, clearer model‑experiment alignment, and more effective collaboration across disciplines. The discussion highlights how accessible systems, real‑time visibility, and cross‑functional coordination allow organizations to move programs forward with greater speed and precision. This episode is sponsored by CDD. Learn how brands work with Emerj and other Emerj Media options at go.emerj.com/partner
Transcribe →
AI That Clinicians Can Trust: Building Reliable Clinical Decision Support with Rhett Alden of Elsevier
Apr 200:24:42Tap to summarizeClinicians face a significant trust gap and administrative burden that hinders the effective deployment of AI at the point of care. In this episode, Rhett Alden, CTO at Elsevier, outlines how integrating transparent, peer-reviewed AI assistants directly into clinical workflows can mitigate physician burnout and reduce medical errors. The discussion examines the governance frameworks, data transparency requirements, and specialized training necessary to shift from skeptical experimentation to scalable, high-impact clinical adoption. Learn how brands work with Emerj and other Emerj Media options at go.emerj.com/partner
Transcribe →
Automated ECOAs That Reduce Risk and Improve Data Quality with Elan Josielewski & Anthony Mikulaschek of IQVIA
Mar 500:28:46Tap to summarizeClinical trials often slow down at the exact points where precision is most critical — manual coding steps, fragmented workflows, and regulatory processes that introduce avoidable risk. In this episode, Elan Josielewski, Senior Director of Patient Centered Solutions at IQVIA, and Tony Mikulaschek, Vice President of eCOA at IQVIA, discuss how connected automation removes these failure points across the ECOA lifecycle. They outline how pre‑validated digital instrument libraries replace months of manual coding with audit‑ready configurations, how automated documentation now covers more than 70% of study requirements, and how automated screenshot generation can produce tens of thousands of localized IRB‑ready pages in under an hour. The conversation focuses on how these capabilities strengthen measurement integrity across global sites while reducing operational risk throughout long, complex trials. Want to share your AI adoption story with executive peers? Click emerj.com/ex2 for more information and to be a potential future guest on Emerj's flagship 'AI in Business' podcast!
Transcribe →
AI-Native Discovery in Pharma - with Alister Campbell of Dotmatics
Feb 500:26:58Tap to summarizeToday's guest is Alister Campbell, Vice President, Global Head of Science and Technology at Dotmatics. Campbell works at the intersection of scientific R&D, data strategy, and applied AI across the drug discovery lifecycle. Alister joins Emerj Client Narrative & Content Strategy Lead Nick Gertsch to discuss how data and AI are shifting pharma R&D from linear, empirical workflows toward tighter, more predictive discovery loops where experiments, simulation, and modeling inform decisions earlier and faster. If you've enjoyed or benefited from some of the insights of this episode, consider leaving us a five-star review on Apple Podcasts, and let us know what you learned, found helpful, or liked most about this show!
Transcribe →
Leading Bold Change and Human-Centered Innovation in Healthcare - with Dr. Imamu Tomlinson of Vituity
Jan 100:22:01Tap to summarizeToday's guest is Dr. Imamu Tomlinson, CEO of Vituity and President of the Vituity Cares Foundation. Vituity is a physician-owned multispecialty partnership with 6,000+ clinicians across 690 locations. Dr. Tomlinson joins Emerj Editorial Director Marilie Fouché to unpack leadership for driving AI-enabled innovation in healthcare's slow ecosystem. Dr. Tomlinson also shares practical takeaways like channeling "disagreeableness" into questions, celebrating early data wins for buy-in, and using AI to offload transactional tasks — freeing time for empathy and human-centered decisions across 13 million annual encounters. Want to share your AI adoption story with executive peers? Click emerj.com/ex2 for more information and to be a potential future guest on Emerj's flagship 'AI in Business' podcast! Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1.
Transcribe →
Reducing Audit Friction and Driving Accountability with AI in Healthcare – with Yasemin Agatan of AdaptHealth
Dec 400:29:52Tap to summarizeToday's guest is Yasemin Agatan, Senior Vice President of Internal Audit at AdaptHealth, a provider of home medical equipment, supplies, and related services supporting patients living at home. Yasemin brings extensive experience in audit, compliance, and operational risk management within the healthcare sector. She joins Emerj Editorial Director Matthew DeMello to discuss how enterprise leaders can leverage data and AI to improve audit workflows, enhance transparency, and manage risk more effectively. Yasemin also highlights practical approaches for organizations, including improving data visibility, implementing structured, explainable processes, and using AI to identify exceptions and inefficiencies, driving measurable gains in speed, accountability, and operational performance. Want to share your AI adoption story with executive peers? Click emerj.com/ex2 for more information and to be a potential future guest on Emerj's flagship 'AI in Business' podcast!
Transcribe →
Driving AI from Pilots to Business Impact in Pharma – with Alyssa Fenoglio of Teva Pharmaceuticals
Nov 600:24:03Tap to summarizeToday's guest is Alyssa Fenoglio, VP, Global Head of Digital Commercial at Teva Pharmaceuticals. Teva is a global pharmaceutical company delivering both generic and specialty medicines across more than 60 countries. Alyssa joins Emerj CEO and Head of Research Daniel Faggella to discuss the unique challenges of digital transformation in life sciences and how organizations can leverage data and AI to create real business impact. She also shares practical strategies for securing leadership support, linking AI pilots to measurable business outcomes, and building cross-functional teams to drive innovation responsibly and at scale. Want to share your AI adoption story with executive peers? Click emerj.com/e2 for more information and to be a potential future guest on Emerj's flagship 'AI in Business' podcast! Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1.
Transcribe →
Driving Audit Workflows in the Era of Agentic AI and IoT for Healthcare - with Yasemin Agatan of Adapt Health
Oct 200:23:48Tap to summarizeInternal audit sits at the crossroads of regulation, data, and business outcomes—nowhere more than in healthcare and medical devices. Yasemin Agatan, Sr. Vice President of Internal Audit at AdaptHealth, joins Emerj Editorial Director Matthew DeMello to unpack what an "AI-ready" audit looks like in one of the most complex and regulated environments. Yasemin lays out today's top pressures: rapidly shifting FDA and HIPAA requirements, thorny revenue recognition and reimbursement models, multi-party contracts, and a deluge of device and platform data. She then maps where AI is already moving the needle—NLP for coding accuracy, automated claims checks, anomaly detection that shortens audit cycles—and how internal audit can lead with governance: creating an AI inventory, partnering with InfoSec, compliance, legal, and data teams, and putting privacy and data minimization at the core. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the 'AI in Business' podcast! If you've enjoyed or benefited from some of the insights of this episode, consider leaving us a five-star review on Apple Podcasts, and let us know what you learned, found helpful, or liked most about this show!
Transcribe →
Dangers of Unchecked AI Development When Politics Meets Machine Learning - with John-Clark Levin of the Yorktown Institute
Sep 400:59:35Tap to summarizeIn this episode of the AI in Healthcare and Life Sciences podcast, host Matthew DeMello speaks with John-Clark Levin, Fellow at the Yorktown Institute and researcher at Kurzweil Research, about the intersection of U.S. politics, AI development, and biosecurity. Levin outlines why the coming years may prove decisive for artificial general intelligence (AGI) and how political volatility under the current administration could directly impact AI safety and regulation. He explains the unique risks of authoritarian tendencies in shaping AI policy, particularly when it comes to epistemics—how governments decide what's true and which advisors they trust. Want to share your AI adoption story with executive peers? Click emerj.com/ex2 for more information and to be a potential future guest on Emerj's flagship' AI in Business' podcast! If you've enjoyed or benefited from some of the insights of this episode, consider leaving us a five-star review on Apple Podcasts, and let us know what you learned, found helpful, or liked most about this show!
Transcribe →